SOLA Biosciences Japan GK, a subsidiary of Boston-based SOLA Biosciences Inc., has received a grant of approximately 6 billion yen from the Japan Agency for Medical Research and Development (AMED) to advance its gene therapy program SOL-257 for amyotrophic lateral sclerosis (ALS). The grant, part of AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, will support the development of SOL-257 over […]















